Comparative Pharmacology
Head-to-head clinical analysis: METHOCARBAMOL versus OZOBAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHOCARBAMOL versus OZOBAX.
METHOCARBAMOL vs OZOBAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methocarbamol is a centrally acting muscle relaxant whose exact mechanism of action is not fully understood. It is thought to produce skeletal muscle relaxation by depressing the central nervous system, possibly via general CNS depression, without directly affecting the neuromuscular junction or skeletal muscle fibers.
OZOBAX (carisoprodol) is a centrally acting skeletal muscle relaxant that does not directly relax skeletal muscle. Its mechanism of action is thought to be related to its sedative properties and its metabolite, meprobamate, which has anxiolytic and sedative effects. Carisoprodol acts as a GABA-A receptor agonist and may also inhibit interneuronal activity in the spinal cord and reticular formation.
METHOCARBAMOL 1500 mg orally 4 times daily or 750 mg orally every 4 hours, or 1-3 g intravenously every 8 hours, not to exceed 3 g/day intravenously for more than 3 consecutive days.
OZOBAX (baclofen) oral: Initial 5 mg three times daily, may increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg four times daily). Intrathecal: Test dose 50-100 mcg, then continuous infusion via pump 22-900 mcg/day.
None Documented
Clinical Note
moderateMethocarbamol + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Methocarbamol is combined with Fluticasone propionate."
Clinical Note
moderateMethocarbamol + Venlafaxine
"The risk or severity of adverse effects can be increased when Methocarbamol is combined with Venlafaxine."
Clinical Note
moderateMethocarbamol + Nefazodone
"The risk or severity of adverse effects can be increased when Methocarbamol is combined with Nefazodone."
Clinical Note
moderateNone Documented
Terminal elimination half-life: 1-2 hours. Clinical context: short half-life necessitates frequent dosing (q6h) for sustained muscle relaxation.
Terminal elimination half-life is approximately 12-15 hours in adults with normal renal function. This supports twice-daily dosing in most patients.
Renal: primarily as glucuronide conjugates and unchanged drug (~50-70% as metabolites, <2% unchanged). Fecal: minimal, <2%. Biliary: not significant.
Primarily renal excretion of unchanged drug (approximately 70-80% of the dose) with minor biliary/fecal elimination (10-15%).
Category A/B
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant
Methocarbamol + Stiripentol
"The risk or severity of adverse effects can be increased when Methocarbamol is combined with Stiripentol."